Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy

Takeda

6 April 2020 - Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.

Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring and Takeda to develop a potential plasma-derived therapy for treating COVID-19. 

The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19.

Read Takeda press release

Michael Wonder

Posted by:

Michael Wonder